NATURAL PRODUCT RESEARCH AND DEVELOPMENT ›› 2025, Vol. 37 ›› Issue (增刊1): 107-115.

Previous Articles     Next Articles

Construction and reversing multidrug resistance study of cationic nanocarrier with paclitaxel and resveratrol co-loaded

JI Ya-wen,ZHANG Pei-yu,LIU Yi-ting,YU Shu-miao,CHEN Cong-hui*   

  1. School of Medicine,Linyi University,Linyi 276000,China
  • Online:2025-09-25 Published:2025-09-22

Abstract:

In order to construct cationic nanocarrier with paclitaxel (PTX) and resveratrol (Rev) co-loaded for reversing multidrug resistance activity.The cationic nanocarrier was prepared by the thin-film dispersion method;The prescription of cationic nanocarrier with PTX and Rev co-loaded was optimized by Box-Behnken response surface method;In vitro drug release study was conducted using dialysis method;The reversing multidrug resistance activity was evaluated by the standard MTT assay.The encapsulation efficiency of PTX and Rev in cationic nanocarrier were 98.93% and 81.23%,respectively;The average particle size was 186.33 nm,and the zeta potential was 6.38 mV;The drug-loaded nanocarrier exhibited significant slow-release drug behavior in vitro;The cytotoxicity studies demonstrated that cationic nanocarrier had high cellular inhibition in drug-resistant cells,the reversal of resistance index was 9.05.The cationic nanocarrier with optimal prescription was suitable for the co-delivery of PTX and Rev,achieved excellent reversing multidrug resistance efficacy.

Key words: paclitaxel, resveratrol, reversing multidrug resistance, Box-Behnken response surface method, cationic nanocarrier

CLC Number: